BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 23749645)

  • 1. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.
    Muir K; Hazim A; He Y; Peyressatre M; Kim DY; Song X; Beretta L
    Cancer Res; 2013 Aug; 73(15):4722-31. PubMed ID: 23749645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia.
    Povero D; Chen Y; Johnson SM; McMahon CE; Pan M; Bao H; Petterson XT; Blake E; Lauer KP; O'Brien DR; Yu Y; Graham RP; Taner T; Han X; Razidlo GL; Liu J
    J Hepatol; 2023 Aug; 79(2):378-393. PubMed ID: 37061197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
    Depner CM; Traber MG; Bobe G; Kensicki E; Bohren KM; Milne G; Jump DB
    PLoS One; 2013; 8(12):e83756. PubMed ID: 24358308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
    Jump DB; Depner CM; Tripathy S; Lytle KA
    Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.
    Chiappini F; Coilly A; Kadar H; Gual P; Tran A; Desterke C; Samuel D; Duclos-Vallée JC; Touboul D; Bertrand-Michel J; Brunelle A; Guettier C; Le Naour F
    Sci Rep; 2017 Apr; 7():46658. PubMed ID: 28436449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
    Haberl EM; Pohl R; Rein-Fischboeck L; Höring M; Krautbauer S; Liebisch G; Buechler C
    Lipids Health Dis; 2020 Dec; 19(1):250. PubMed ID: 33298075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice.
    Watanabe S; Horie Y; Kataoka E; Sato W; Dohmen T; Ohshima S; Goto T; Suzuki A
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S96-S100. PubMed ID: 17567478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
    Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
    Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.
    Yang H; Deng Q; Ni T; Liu Y; Lu L; Dai H; Wang H; Yang W
    Int J Biol Sci; 2021; 17(15):4207-4222. PubMed ID: 34803493
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.
    Rappa F; Greco A; Podrini C; Cappello F; Foti M; Bourgoin L; Peyrou M; Marino A; Scibetta N; Williams R; Mazzoccoli G; Federici M; Pazienza V; Vinciguerra M
    PLoS One; 2013; 8(1):e54458. PubMed ID: 23372727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
    Torres DM; Harrison SA
    Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
    Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor suppressor gene PTEN and non-alcoholic steatohepatitis (NASH)].
    Sato W; Horie Y; Watanabe S; Suzuki A
    Nihon Rinsho; 2005 Aug; 63(8):1475-83. PubMed ID: 16101243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
    Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
    J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.